FDA Adverse Event Injury Summary report: N

FREESTYLE LIBRE 2

MDR report key: 18191147 · Received November 22, 2023

Report

Report Number
2954323-2023-51022
Event Type
Injury
Date Received
November 22, 2023
Date of Event
November 17, 2023
Report Date
March 1, 2024
Manufacturer
ABBOTT DIABETES CARE INC
Product Code
QLG
UDI-DI
00357599800000
PMA / PMN Number
K193371
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
SC, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 0

SENSOR (B)(6) HAS BEEN RETURNED AND INVESTIGATED. THE SENSOR PLUG IS PROPERLY SEATED AND NO PHYSICAL DAMAGE WAS OBSERVED ON THE SENSOR PATCH. EXTRACTED DATA FROM THE RETURNED SENSOR USING APPROVED SOFTWARE. THE SENSOR WAS FOUND TO BE IN SENSOR STATE 5 (INDICATING NORMAL TERMINATION). VISUAL INSPECTION HAS BEEN PERFORMED ON THE SENSOR PLUG ASSEMBLY, NO FAILURE MODES WERE OBSERVED. SIM VIVO TESTING (SIMULATION OF THE ELECTRICAL SIGNAL PRODUCED BY THE SENSOR TAIL) AND POISE VOLTAGE TESTING WERE PERFORMED AND ALL RESULTS WERE WITHIN SPECIFICATION. NO MALFUNCTION OR PRODUCT DEFICIENCY WAS IDENTIFIED. THEREFORE, THE ISSUE IS NOT CONFIRMED. ALL PERTINENT INFORMATION AVAILABLE TO ABBOTT DIABETES CARE HAS BEEN SUBMITTED.

Additional Manufacturer Narrative · 0

SENSOR (B)(6) HAS BEEN RETURNED AND INVESTIGATED. THE SENSOR PLUG IS PROPERLY SEATED AND NO PHYSICAL DAMAGE WAS OBSERVED ON THE SENSOR PATCH. EXTRACTED DATA FROM THE RETURNED SENSOR USING APPROVED SOFTWARE. THE SENSOR WAS FOUND TO BE IN SENSOR STATE STATE 3 (INDICATING THE SENSOR WAS PAIRED WITHIN THE LAST 14 DAYS). VISUAL INSPECTION HAS BEEN PERFORMED ON THE SENSOR PLUG ASSEMBLY, NO FAILURE MODES WERE OBSERVED. SIM VIVO TESTING (SIMULATION OF THE ELECTRICAL SIGNAL PRODUCED BY THE SENSOR TAIL) AND POISE VOLTAGE TESTING WERE PERFORMED AND ALL RESULTS WERE WITHIN SPECIFICATION. NO MALFUNCTION OR PRODUCT DEFICIENCY WAS IDENTIFIED. THEREFORE, THE ISSUE IS NOT CONFIRMED. ALL PERTINENT INFORMATION AVAILABLE TO ABBOTT DIABETES CARE HAS BEEN SUBMITTED.THIS SERVES AS A CORRECTION REPORT.

Additional Manufacturer Narrative · 0

THE PRODUCT HAS BEEN REQUESTED BACK FOR AN INVESTIGATION. AT THIS TIME PRODUCT HAS NOT YET BEEN RETURNED. AN EXTENDED INVESTIGATION HAS BEEN PERFORMED FOR THE REPORTED COMPLAINT AND IT HAS BEEN DETERMINED THAT THERE WAS NO INDICATION THAT THE PRODUCT DID NOT MEET SPECIFICATION. THE DEVICE HISTORY RECORDS (DHRS) FOR THE FS LIBRE SENSOR AND FS LIBRE SENSOR KIT WERE REVIEWED AND THE DHRS SHOWED THE FS LIBRE SENSOR AND SENSOR KIT PASSED ALL TESTS PRIOR TO RELEASE. IF THE PRODUCT IS RETURNED, A PHYSICAL INVESTIGATION WILL BE PERFORMED AND A FOLLOW-UP REPORT SUBMITTED. ALL PERTINENT INFORMATION AVAILABLE TO ABBOTT DIABETES CARE HAS BEEN SUBMITTED.

Description of Event or Problem · 0

AN ERROR MESSAGE WAS REPORTED WITH THE ABBOTT DIABETES CARE (ADC) DEVICE. CUSTOMER RECEIVED A "REPLACE SENSOR" MESSAGE AND WAS UNABLE TO OBTAIN READINGS. AS A RESULT, CUSTOMER EXPERIENCED A LOSS OF CONSCIOUSNESS AND WAS UNABLE TO SELF-TREAT, REQUIRING THIRD-PARTY TREATMENT OF "BAQSIMI® (GLUCAGON) NASAL POWDER" (DOSE UNSPECIFIED), URSODIOL (DOSE UNSPECIFIED), IMURAN (DOSE UNSPECIFIED), MELOXICAM (DOSE UNSPECIFIED), AND LITHIUM (DOES UNSPECIFIED) BY A NON-HEALTHCARE PROFESSIONAL. THERE WAS NO REPORT OF DEATH OR PERMANENT IMPAIRMENT ASSOCIATED WITH THIS EVENT.

Description of Event or Problem · 0

AN ERROR MESSAGE WAS REPORTED WITH THE ABBOTT DIABETES CARE (ADC) DEVICE. CUSTOMER RECEIVED A "REPLACE SENSOR" MESSAGE AND WAS UNABLE TO OBTAIN READINGS. AS A RESULT, CUSTOMER EXPERIENCED A LOSS OF CONSCIOUSNESS AND WAS UNABLE TO SELF-TREAT, REQUIRING THIRD-PARTY TREATMENT OF "BAQSIMI® (GLUCAGON) NASAL POWDER" (DOSE UNSPECIFIED), URSODIOL (DOSE UNSPECIFIED), IMURAN (DOSE UNSPECIFIED), MELOXICAM (DOSE UNSPECIFIED), AND LITHIUM (DOES UNSPECIFIED) BY A NON-HEALTHCARE PROFESSIONAL. THERE WAS NO REPORT OF DEATH OR PERMANENT IMPAIRMENT ASSOCIATED WITH THIS EVENT.

Description of Event or Problem · 0

AN ERROR MESSAGE WAS REPORTED WITH THE ABBOTT DIABETES CARE (ADC) DEVICE. CUSTOMER RECEIVED A "REPLACE SENSOR" MESSAGE AND WAS UNABLE TO OBTAIN READINGS. AS A RESULT, CUSTOMER EXPERIENCED A LOSS OF CONSCIOUSNESS AND WAS UNABLE TO SELF-TREAT, REQUIRING THIRD-PARTY TREATMENT OF "BAQSIMI® (GLUCAGON) NASAL POWDER" (DOSE UNSPECIFIED), URSODIOL (DOSE UNSPECIFIED), IMURAN (DOSE UNSPECIFIED), MELOXICAM (DOSE UNSPECIFIED), AND LITHIUM (DOES UNSPECIFIED) BY A NON-HEALTHCARE PROFESSIONAL. THERE WAS NO REPORT OF DEATH OR PERMANENT IMPAIRMENT ASSOCIATED WITH THIS EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
722500 FREESTYLE LIBRE 2 FLASH GLUCOSE MONITORING SYSTEM QLG ABBOTT DIABETES CARE INC 71992-01 00357599800000

Patients

Seq Age Sex Outcome Treatment
1 40 YR Male Required Intervention